ERK-METTL3 axis acts as a novel regulator of antiviral innate immunity combating pseudorabies virus infection

Lucai Wang1, Xiangqi Qiu1, Lele Wang1

  • 1International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.

Plos Pathogens
|August 13, 2025
PubMed

Insights

The ERK-METTL3 axis regulates antiviral immunity. ERK2 phosphorylation of METTL3 enhances the type I interferon response against alpha-herpesvirus, offering new antiviral strategies.

Area of Science:

  • Immunology
  • Virology
  • Molecular Biology
  • Epigenetics

Background:

  • The methyltransferase METTL3 regulates cell processes, but its role in antiviral immunity is unknown.
  • ERK-mediated phosphorylation of METTL3 impacts stem cell differentiation and cancer.

Purpose of the Study:

  • To investigate the role of ERK-mediated METTL3 phosphorylation in the antiviral innate immune response.
  • To elucidate the mechanism by which this interaction affects viral replication and host defense.

Main Methods:

  • In vitro and in vivo studies using Pseudorabies virus (PRV) infection models.
  • Analysis of protein expression (ERK2, METTL3), viral replication, and immune pathways (IFN-β, NF-κB).
  • Site-directed mutagenesis and inhibitor studies to assess the functional importance of METTL3 phosphorylation.

Main Results:

  • ERK2 expression increased, while METTL3 decreased during PRV infection.
  • Overexpression of ERK2 and METTL3 reduced viral replication; knockdown enhanced it.
  • ERK2 phosphorylates METTL3 at Serine 43, boosting the type I interferon response via NF-κB activation, m6A modification, and protein translation.
  • Inhibitor treatments promoted viral replication and mortality in mice by suppressing IFN-β.

Conclusions:

  • Phosphorylation-dependent crosstalk between MAPK signaling and m6A machinery is crucial for antiviral defense.
  • METTL3 Serine 43 is a key site for immune regulation during alpha-herpesvirus infection.
  • The ERK-METTL3 axis is a novel regulator of antiviral innate immunity, presenting potential host-directed therapeutic targets.